FOLH1 and metastatic prostate carcinoma: Herein, we report the formulation of a single-vial freeze-dried PSMA-617 kit, preparation of patient doses of 177Lu-PSMA-617 using the kit, detailed radiochemical studies with respect to the formulation of 177Lu-PSMA-617 using the lyophilized kit, pharmacokinetic evaluation of 177Lu-PSMA-617 in a healthy small animal model, and administration of the radiolabeled preparation in patients suffering from metastatic prostate cancer.